A new study highlights the potential of gene expression profiling (40-GEP) in improving risk prediction for patients with high-risk cutaneous squamous cell carcinoma (cSCC). By combining molecular data with established clinical staging systems, healthcare providers can better personalize treatment plans and surveillance strategies, ultimately enhancing patient outcomes.
In this issue
Rate this content's potential impact on patient outcomes
Average rating / 5. Vote count:
No votes so far! Be the first to rate this content.
Latest articles
All articles


